Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Troglitazone in type II diabetes mellitus

N Sparano1, T L Seaton

  • 1Department of Pharmacy Practice, Wilkes University, Wilkes-Barre, Pennsylvania 18766, USA.

Pharmacotherapy
|June 10, 1998
PubMed
Summary

Troglitazone enhances insulin sensitivity for type II diabetes, offering potential benefits like reduced insulin needs. However, its limited advantages over other treatments and risks necessitate careful patient selection and monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do patients prefer transdermal fentanyl or sustained-release oral morphine for treatment of chronic non-cancer pain?

The Journal of family practice·2001
Same author

Does hormone replacement therapy (HRT) improve cognitive function or either delay or prevent dementia in postmenopausal women?

The Journal of family practice·2001
Same author

Is the combination of ibuprofen and caffeine effective for the treatment of a tension-type headache?

The Journal of family practice·2001
Same author

What is the optimal strategy for managing acute migraine headaches?

The Journal of family practice·2001
Same author

How does liquid docusate sodium (Colace) compare with triethanolamine polypeptide as a ceruminolytic for acute earwax removal?

The Journal of family practice·2000
Same author

What is the optimal treatment for lateral ankle ligament ruptures?

The Journal of family practice·2000

Area of Science:

  • Pharmacology and Therapeutics
  • Endocrinology and Metabolism

Background:

  • Troglitazone is an antihyperglycemic agent for type II diabetes mellitus.
  • It improves insulin sensitivity rather than stimulating insulin secretion.

Purpose of the Study:

  • To evaluate the potential advantages and disadvantages of troglitazone.
  • To determine its place in therapy for type II diabetes mellitus.

Main Methods:

  • Review of available information on troglitazone's efficacy and safety.
  • Comparison with existing oral antihyperglycemic agents and insulin.

Main Results:

  • Potential benefits include decreased insulin requirements and reduced hypoglycemia risk.
  • Disadvantages include cytochrome P450 induction, risk of liver injury, and higher cost.
  • Limited demonstrated benefit over sulfonylureas or metformin in monotherapy or combination.

Conclusions:

  • Troglitazone offers an alternative mechanism for glycemic control by enhancing insulin sensitivity.
  • Its use should be reserved for patients with poor glycemic control on high-dose insulin pending further comparative studies.
  • Routine monitoring of serum transaminases is crucial due to rare idiosyncratic hepatocellular injury.

Related Experiment Videos